Ficu Mihaela, Niculescu-Duvaz Dan, Aljarah Mohammed, Springer Caroline, Kershaw Christopher S
CRUK Manchester Institute: Cancer Research UK Manchester Institute, DDU, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND.
Oncodrug LTD, Drug Discovery, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND.
Chembiochem. 2025 May 2:e202500133. doi: 10.1002/cbic.202500133.
The phenotypic effect induced by a Proteolysis-Targeting Chimera (PROTAC) can depend on several factors, including the E3 ligase recruited. For the discovery of a first-in-class PROTAC for a target of interest, the E3 ligases commonly hijacked remain the Von Hippel-Lindau (VHL) and Cereblon (CRBN) since potent and accessible ligands are readily available to recruit them. Mouse double minute 2 (MDM2) E3 ligase stands out because it regulates p53 levels to maintain cellular homeostasis. However, the synthesis of the most potent MDM2 ligands remains very complex. Here we report the discovery of novel MDM2-recruiting PROTACs incorporating rac-Nutlin-3 as a ligand with an easier synthetic tractability, further demonstrating its potential in this technology. The most promising degrader, PROTAC 3, showed preferential degradation of the BRD4 short isoform and c-Myc compared with MZ1, a validated VHL-based PROTAC.
蛋白酶靶向嵌合体(PROTAC)诱导的表型效应可能取决于多个因素,包括所招募的E3连接酶。为了发现针对目标靶点的首个PROTAC,常用的被劫持E3连接酶仍然是冯·希佩尔-林道(VHL)和大脑神经酰胺酶(CRBN),因为有强效且易于获取的配体可用于招募它们。小鼠双微体2(MDM2)E3连接酶很突出,因为它调节p53水平以维持细胞内稳态。然而,最有效的MDM2配体的合成仍然非常复杂。在此我们报告发现了新型结合rac-纽蛋白-3作为配体的招募MDM2的PROTAC,其合成更易于操作,进一步证明了其在该技术中的潜力。最有前景的降解剂PROTAC 3与经过验证的基于VHL的PROTAC MZ1相比,显示出对BRD4短异构体和c-Myc的优先降解作用。